Vimarsana
Biggest News Aggregation in the World

Trial Hotline News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Trial Hotline. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Trial Hotline Today - Breaking & Trending Today

Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting - Vimarsana News

Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting

Published: December 12, 2022

/PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced updated clinical data from the pirtobrutinib global Phase...

Source: prnewswire.com
Related Topics:
United StatesSusan ObrienJoe FletcherKyle OwensDavid HymanEli LillyUniversity Of CaliforniaChao Family Comprehensive Cancer CenterLilly United StatesAmerican Society Of HematologyExchange CommissionSusano BrienLymphocytic LeukemiaSmall Lymphocytic LymphomaCell LymphomaTrial HotlinePrivate Securities Litigation Reform ActUnited States Securities
Loxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting - Vimarsana News

Loxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting

Published: November 3, 2022

INDIANAPOLIS, Nov. 3, 2022 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that study investig...

Source: businessinsider.com
Related Topics:
United StatesNew OrleansWilliamg WierdaJoe FletcherMichaell WangKyle OwensEli LillyNiravn ShahAnthonyr MatoDrugs In DevelopmentLilly United StatesAmerican Society Of HematologyExchange CommissionAmerican SocietyAnnual MeetingHighly SelectiveTheaterc PresenterTargeted Triplet CombinationsMalignancies Who Were Previously IntolerantPosteri DateHalld PresenterCell LymphomaAdditional PatientsTrial HotlinePrivate Securities Litigation Reform Act
Lilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR) - Vimarsana News

Lilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR)

Published: March 8, 2022

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from the pirtobrutinib and Verzenio® (abemaciclib) development programs will be...

Source: prnewswire.com
Related Topics:
United StatesLauren CohenKevin HernEli LillyExchange CommissionAmerican Association For Cancer ResearchLilly Research LaboratoriesCancer ResearchAnnual MeetingPhasei Clinical TrialsExhibit Hallsd HPoster SectionCell Cycle ControlCell Cycle RegulatorsLoxo OncologyTrial HotlineResponse RateVerzenio AcrossFor GradeGrade VenousPrescribing InformationPrivate Securities Litigation Reform ActUnited States SecuritiesEli Lilly And CompanyHealth Care Amp Hospitals
Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting - Vimarsana News

Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting

Published: December 12, 2021

/PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced updated clinical data from the...

Source: prnewswire.com
Related Topics:
United StatesLauren CohenKevin HernMichael WangDavid HymanEli LillyExchange CommissionLilly Research LaboratoriesUniversity Of Texas Md Anderson Cancer CenterPuddin Clarke Endowed ProfessorCancer CenterData PresentedLoxo OncologyLilly PhysicianTrial HotlineResponse RatePrivate Securities Litigation Reform ActUnited States SecuritiesEli Lilly And Company
Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting - Vimarsana News

Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting

Published: December 12, 2021

/PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced updated clinical data from the...

Source: prnewswire.com
Related Topics:
United StatesLauren CohenKevin HernMichael WangDavid HymanEli LillyExchange CommissionLilly Research LaboratoriesUniversity Of Texas Md Anderson Cancer CenterPuddin Clarke Endowed ProfessorCancer CenterData PresentedLoxo OncologyLilly PhysicianTrial HotlineResponse RatePrivate Securities Litigation Reform ActUnited States SecuritiesEli Lilly And Company